CIK 0001640266 · Accelerated filer<br>Smaller reporting company
Voyager Therapeutics, Inc.
Sign in to watch- Ticker
- VYGR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-259-5340
- Business address
- 75 HAYDEN AVENUE, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-18 | Carter Todd Alfred Chief Scientific Officer | Sale 10b5-1 | −3,301 | $3.44 | $11K | 149,892 |
| 2026-02-18 | Sandrock Alfred President and CEO | Sale 10b5-1 | −11,732 | $3.41 | $40K | 498,257 |
| 2026-02-10 | Swartz Robin COO & CBO | Sale | −4,569 | $3.85 | $18K | 210,078 |
| 2026-02-10 | Sandrock Alfred President and CEO | Sale | −12,192 | $3.78 | $46K | 509,989 |
| 2026-02-10 | Carter Todd Alfred Chief Scientific Officer | Sale | −3,525 | $3.85 | $14K | 153,193 |
| 2026-02-06 | Ferguson Toby Chief Medical Officer | Grant or award | +45,000 | 183,914 | ||
| 2026-02-06 | Ferguson Toby Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +210,000 | 210,000 | ||
| 2026-02-06 | Carter Todd Alfred Chief Scientific Officer | Grant or award | +33,000 | 156,718 | ||
| 2026-02-06 | Carter Todd Alfred Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +154,000 | 154,000 | ||
| 2026-02-06 | Swartz Robin COO & CBO | Grant or award | +45,000 | 214,647 | ||
| 2026-02-06 | Swartz Robin COO & CBO | Grant or award · Stock Option (Right to Buy) | +210,000 | 210,000 | ||
| 2026-02-06 | Sandrock Alfred President and CEO | Grant or award | +86,250 | 522,181 | ||
| 2026-02-06 | Sandrock Alfred President and CEO | Grant or award · Stock Option (Right to Buy) | +402,500 | 402,500 | ||
| 2026-02-06 | Jorgensen Nathan D. Chief Financial Officer | Grant or award | +32,250 | 156,084 | ||
| 2026-02-06 | Jorgensen Nathan D. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +150,500 | 150,500 | ||
| 2026-01-06 | Shiferman Gregory L. SVP and General Counsel | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-10-03 | Jorgensen Nathan D. Chief Financial Officer | Sale 10b5-1 | −7,666 | $4.78 | $37K | 123,834 |
| 2025-08-18 | Ferguson Toby Chief Medical Officer | Sale | −19,000 | $3.73 | $71K | 138,914 |
| 2025-06-03 | Vitale Nancy Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2025-06-03 | SCANGOS GEORGE A Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 |
Page 2 of 7 · 130 trades